



February 25, 2016

## **Ardelyx to Report Fourth Quarter and Full Year 2015 Financial Results on March 4th, 2016**

FREMONT, Calif., Feb. 25, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2015, on Friday, March 4, 2016. Following the announcement, the Ardelyx management team will host a live conference call and webcast at 8:00am ET to review the Company's financial results and provide a business update.



The live webcast can be accessed by visiting the investor section of Ardelyx's website at [ir.ardelyx.com](http://ir.ardelyx.com). Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-855-296-9612 (US) or 920-663-6277 (International) to listen to the conference call. The conference ID number for the live call will be 58231765. Following the webcast, an archived version of the call will be available until March 18, 2016.

### **About Ardelyx**

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of constipation-predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end stage renal disease. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at [www.ardelyx.com](http://www.ardelyx.com).

Logo - <http://photos.prnewswire.com/prnh/20140619/119451>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-full-year-2015-financial-results-on-march-4th-2016-300225948.html>

SOURCE Ardelyx

News Provided by Acquire Media